Barr Laboratories Inc. was founded in 1970 by Edwin A. Cohen and was ultimately taken public under his leadership. On July 18, 2008; it was announced that rival firm, Teva Pharmaceutical Industries Ltd. would acquire Barr Pharmaceuticals Inc. for $7.46 billion plus the assumption of net debt of approximately $1.5 billion.
At Teva Pharmaceutical Industries, we improve people's health through our products, integrated R&D, generic medicines and global businesses.
Barr Laboratories, Inc. is now part of Teva Pharmaceutical Industries Ltd. (July 2008). See: Teva Pharmaceuticals USA, Inc. Latest Drug Information Updates. Erleada Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of men with non-metastatic... Symdeko Symdeko (ivacaftor / tezacaftor tablets ...
Company profile & key executives for Barr Laboratories Inc (0293099D:-) including description, corporate address, management team and contact info.
Barr Laboratories, Inc. is a specialty pharmaceutical company engaged in developing, manufacturing and marketing generic and proprietary pharmaceuticals. A research-intensive pharmaceutical company, Barr is listed on the New York Stock Exchange (NYSE-BRL). With fiscal 2003 revenues of $903 million, the Company ...
California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs' attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny. Generic Drugs Legal Issues. Bookmark. 11 May 2015 ...
Jan 26, 2017 ... Teva Pharmaceutical Industries Ltd's Barr Laboratories Inc has reached a $225 million settlement in an antitrust class action that accused the drugmaker of keeping a generic version of Bayer AG's antibiotic Cipro off the market, court documents showed.
Jun 30, 2001 ... The drug maker Barr Laboratories Inc. said yesterday that it would acquire Duramed Pharmaceuticals Inc. in a stock swap valued at about $589 million, adding to Barr's line of oral contraceptives and hormone products for women. Barr said it would exchange one share of its stock for 3.9032 shares of ...
Oct 24, 2017 ... The Food and Drug Administration (FDA) is withdrawing approval of 54 abbreviated new drug applications (ANDAs) from two applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be...